Examples of using Idelalisib in English and their translations into German
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Ecclesiastic
-
Political
-
Computer
-
Programming
-
Official/political
-
Political
Idelalisib induced lymphoid depletion in spleen,
Idelalisib should not be co-administered with colchicine to patients with renal or hepatic impairment.
Idelalisib has not been studied in patients with chronic active hepatitis including viral hepatitis.
Idelalisib is 93% to 94% bound to human plasma proteins at concentrations observed clinically.
The active substance in Zydelig, idelalisib, blocks the effects of an enzyme called PI3K-delta.
Idelalisib is metabolised primarily via aldehyde oxidase,
Animal studies indicate the potential for harmful effects of idelalisib on fertility and foetal development see section 5.3.
Idelalisib is metabolised primarily via aldehyde oxidase,
There is a potential risk that idelalisib, via its major metabolite, GS-563117, may cause photosensitivity in treated patients.
be monitored upon co-administration and following ceasing treatment with idelalisib.
The adverse drug reactions reported with idelalisib alone or in combination with anti-CD20 monoclonal antibodies(rituximab
Solid line: idelalisib+ O(N 174),
Do not take Zydelig if you are allergic to idelalisib or any of the other ingredients of this medicine listed in section 6.
Potential interactions between idelalisib and co-administered medicinal products that are CYP3A substrates are listed in Table 1 increase is indicated as“↑”.
blocking its effects, idelalisib causes death of the cancer cells,
A study of pharmacokinetics and safety of idelalisib was performed in healthy subjects
A study of pharmacokinetics and safety of idelalisib was performed in healthy subjects
In addition, 86 subjects from this study who were randomised to receive placebo+ rituximab went on to receive idelalisib as a single agent in an extension study study 312-0117.
The effect of idelalisib(150 mg
Currently, the Company is investigating the combination of MOR208 and idelalisib in this study.